Poland’s medical cannabis sector has delivered one of the most impressive growth trajectories in Europe—but also one of its sharpest reversals. As the third-largest market on the continent, it has all the ingredients for long-term success: liberal prescribing rules, pharmaceutical legitimacy, high patient demand, and until recently, also a dynamic telemedicine sector.
But in late 2024, it hit a snag: A regulatory backlash against online prescriptions wiped out half the market in just two months. What happened wasn’t a failure of medical cannabis or telemedicine — it was a failure of standards. And unless other countries learn from Poland’s example in governing digital prescription models, they could face the same fate.
The Rise of Poland’s Digital Access Model
At the heart of Poland’s cannabis boom was a remarkable innovation in terms of access: licensed telemedicine platforms that offered fast, low-cost consultations to patients across the country—especially in rural areas underserved by traditional doctors or among populations less likely to visit. This model, proven in other global jurisdictions such as Germany and Australia, filled a crucial gap for patients who might otherwise never have seen a doctor.
“Some platforms have completely eliminated the consultation stage, while others have automated the process to the point of trivializing the medical act”
The model worked like this: a patient filled out a standardized digital admission form, often describing chronic conditions such as insomnia, anxiety or chronic pain. A doctor — sometimes after a brief video consultation, sometimes based solely on the information sent — would review the case and issue a prescription if appropriate. The entire process could take less than 30 minutes, and the medication was often delivered to the patient within a few days.
Read the full article here
